These studies provide a combinatorial approach for inhibiting FOXM1 expression and impairing tumor cell viability that may prove particularly useful in MM and other tumor types characterized by aberrant mitochondrial oxidant production. This evidence concerns the gene FOXM1 and Miyoshi myopathy.